Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We analysed by immunocytochemistry metalloproteinase (MMP)-2 and MMP-9 expression in bone marrow cells from 54 acute myeloid leukaemia (AML) patients, 153 myelodysplastic syndrome (MDS) patients, and 52 non-haemopathic subjects, in order to evaluate whether MMP expression abnormalities were associated with relevant laboratory or clinical findings. In normal samples MMP-2 was detected in rare myeloid cells, MMP-9 in most maturing myeloid cells. In MDS MMP-2 myeloid levels were higher than in controls (P <0.0001); MMP-2 and MMP-9 were often co-expressed. Also many erythroblasts expressed MMP-2. There was a positive correlation between MMP-2 erythroblast expression and erythroid dysplasia (P = 0.002) and an inverse correlation between MMP-2 or MMP-9 myeloid expression and blast cell percentage (P = 0.05 and P = 0.04 respectively). High MMP levels in myeloid cells were associated with longer overall survival (P = 0.03) and evolution-free survival (P = 0.04). In AML MMP-2 levels were lower than in MDS (P <0.0001) and MMP-9 levels lower than in MDS and controls (P <0.0001). MMP levels did not predict response to therapy. The release of active MMPs was detected by colorimetric analysis in cell cultures from representative MDS and AML cases. In conclusion, we have demonstrated an abnormal MMP expression in AML as well as in MDS. The production and release of these enzymes may influence haematopoietic cell behaviour. In MDS, the detection of MMP deregulated expression may be important also from the clinical point of view: it may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments.

Original languageEnglish
Pages (from-to)216-226
Number of pages11
JournalEuropean Journal of Haematology
Volume80
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Matrix Metalloproteinase 2
Myelodysplastic Syndromes
Matrix Metalloproteinase 9
Matrix Metalloproteinases
Acute Myeloid Leukemia
Myeloid Cells
Erythroblasts
Survival

Keywords

  • Acute myeloid leukaemia
  • Immunocytochemistry
  • Matrix metalloproteinase-2
  • Matrix metalloproteinase-9
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

@article{a4e495d3e97e4025a8a67caa8c70f390,
title = "Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes",
abstract = "We analysed by immunocytochemistry metalloproteinase (MMP)-2 and MMP-9 expression in bone marrow cells from 54 acute myeloid leukaemia (AML) patients, 153 myelodysplastic syndrome (MDS) patients, and 52 non-haemopathic subjects, in order to evaluate whether MMP expression abnormalities were associated with relevant laboratory or clinical findings. In normal samples MMP-2 was detected in rare myeloid cells, MMP-9 in most maturing myeloid cells. In MDS MMP-2 myeloid levels were higher than in controls (P <0.0001); MMP-2 and MMP-9 were often co-expressed. Also many erythroblasts expressed MMP-2. There was a positive correlation between MMP-2 erythroblast expression and erythroid dysplasia (P = 0.002) and an inverse correlation between MMP-2 or MMP-9 myeloid expression and blast cell percentage (P = 0.05 and P = 0.04 respectively). High MMP levels in myeloid cells were associated with longer overall survival (P = 0.03) and evolution-free survival (P = 0.04). In AML MMP-2 levels were lower than in MDS (P <0.0001) and MMP-9 levels lower than in MDS and controls (P <0.0001). MMP levels did not predict response to therapy. The release of active MMPs was detected by colorimetric analysis in cell cultures from representative MDS and AML cases. In conclusion, we have demonstrated an abnormal MMP expression in AML as well as in MDS. The production and release of these enzymes may influence haematopoietic cell behaviour. In MDS, the detection of MMP deregulated expression may be important also from the clinical point of view: it may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments.",
keywords = "Acute myeloid leukaemia, Immunocytochemistry, Matrix metalloproteinase-2, Matrix metalloproteinase-9, Myelodysplastic syndrome",
author = "Erica Travaglino and Chiara Benatti and Luca Malcovati and Porta, {Matteo Giovanni Della} and Anna Gall{\`i} and Elisa Bonetti and Vittorio Rosti and Mario Cazzola and Rosangela Invernizzi",
year = "2008",
month = "3",
doi = "10.1111/j.1600-0609.2007.01012.x",
language = "English",
volume = "80",
pages = "216--226",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes

AU - Travaglino, Erica

AU - Benatti, Chiara

AU - Malcovati, Luca

AU - Porta, Matteo Giovanni Della

AU - Gallì, Anna

AU - Bonetti, Elisa

AU - Rosti, Vittorio

AU - Cazzola, Mario

AU - Invernizzi, Rosangela

PY - 2008/3

Y1 - 2008/3

N2 - We analysed by immunocytochemistry metalloproteinase (MMP)-2 and MMP-9 expression in bone marrow cells from 54 acute myeloid leukaemia (AML) patients, 153 myelodysplastic syndrome (MDS) patients, and 52 non-haemopathic subjects, in order to evaluate whether MMP expression abnormalities were associated with relevant laboratory or clinical findings. In normal samples MMP-2 was detected in rare myeloid cells, MMP-9 in most maturing myeloid cells. In MDS MMP-2 myeloid levels were higher than in controls (P <0.0001); MMP-2 and MMP-9 were often co-expressed. Also many erythroblasts expressed MMP-2. There was a positive correlation between MMP-2 erythroblast expression and erythroid dysplasia (P = 0.002) and an inverse correlation between MMP-2 or MMP-9 myeloid expression and blast cell percentage (P = 0.05 and P = 0.04 respectively). High MMP levels in myeloid cells were associated with longer overall survival (P = 0.03) and evolution-free survival (P = 0.04). In AML MMP-2 levels were lower than in MDS (P <0.0001) and MMP-9 levels lower than in MDS and controls (P <0.0001). MMP levels did not predict response to therapy. The release of active MMPs was detected by colorimetric analysis in cell cultures from representative MDS and AML cases. In conclusion, we have demonstrated an abnormal MMP expression in AML as well as in MDS. The production and release of these enzymes may influence haematopoietic cell behaviour. In MDS, the detection of MMP deregulated expression may be important also from the clinical point of view: it may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments.

AB - We analysed by immunocytochemistry metalloproteinase (MMP)-2 and MMP-9 expression in bone marrow cells from 54 acute myeloid leukaemia (AML) patients, 153 myelodysplastic syndrome (MDS) patients, and 52 non-haemopathic subjects, in order to evaluate whether MMP expression abnormalities were associated with relevant laboratory or clinical findings. In normal samples MMP-2 was detected in rare myeloid cells, MMP-9 in most maturing myeloid cells. In MDS MMP-2 myeloid levels were higher than in controls (P <0.0001); MMP-2 and MMP-9 were often co-expressed. Also many erythroblasts expressed MMP-2. There was a positive correlation between MMP-2 erythroblast expression and erythroid dysplasia (P = 0.002) and an inverse correlation between MMP-2 or MMP-9 myeloid expression and blast cell percentage (P = 0.05 and P = 0.04 respectively). High MMP levels in myeloid cells were associated with longer overall survival (P = 0.03) and evolution-free survival (P = 0.04). In AML MMP-2 levels were lower than in MDS (P <0.0001) and MMP-9 levels lower than in MDS and controls (P <0.0001). MMP levels did not predict response to therapy. The release of active MMPs was detected by colorimetric analysis in cell cultures from representative MDS and AML cases. In conclusion, we have demonstrated an abnormal MMP expression in AML as well as in MDS. The production and release of these enzymes may influence haematopoietic cell behaviour. In MDS, the detection of MMP deregulated expression may be important also from the clinical point of view: it may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments.

KW - Acute myeloid leukaemia

KW - Immunocytochemistry

KW - Matrix metalloproteinase-2

KW - Matrix metalloproteinase-9

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=39149091719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149091719&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2007.01012.x

DO - 10.1111/j.1600-0609.2007.01012.x

M3 - Article

C2 - 18081721

AN - SCOPUS:39149091719

VL - 80

SP - 216

EP - 226

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -